Girerd X, Laroche P, Hanon O, Pannier B, Postel-Vinay N, Mourad J-J
Comité français de lutte contre l'hypertension artérielle (CFLHTA), 5, rue des Colonnes-du-Trône, 75012 Paris, France.
Ann Cardiol Angeiol (Paris). 2012 Jun;61(3):213-7. doi: 10.1016/j.ancard.2012.05.003. Epub 2012 May 26.
Describe how antihypertensive drugs are prescribed in France in 2009 and 2010 and assess the effect of the presence of cardiovascular disease on the characteristics of the treatment.
The French League Against Hypertension Surveys (FLAHS) are conducted among a representative sample of individuals aged 35 years and older living in France. For the 2009 and 2010 surveys, a sample of 2292 subjects who declared to take one or more antihypertensive drug has been studied. In addition to the details of antihypertensive medications taken the day of the survey, the personal history for cardiovascular diseases was compiled.
Of the 2292 prescriptions with at least one antihypertensive prescription frequencies are: ARB (43%), diuretics (43%), beta-blockers (34%), CCB (26%), ACEI (26%), spironolactone (8%), central and alpha (7%), DRI (1%). The prescription is performed as monotherapy (42%), bitherapy (37%), triple therapy (16%) and quadruple or more (5%). When triple therapy is prescribed, there is an association ACEI or ARB or DRI+Diu+BB in 46%, and an association ACEI or ARB or DRI+Diu+AC in 30%. Cardiovascular disease is present or past reported by 24% of hypertensive patients: coronary artery disease (13%), heart failure (6%), arrhythmias (5%), stroke (4%), PAD (4%). The use of BB is more common in hypertensive patients who have coronary artery disease, heart failure and arrhythmia. ACE inhibitors are more common in hypertensive patients with coronary artery disease, heart failure or stroke. CCB are more frequent in cases of coronary artery disease or PAD. The ARB are less frequent in patients with coronary artery disease.
The ARB, diuretics and beta-blockers are the most prescribed antihypertensives in France in 2009 to 2010. Cardiovascular diseases declared in 24% of hypertensives led to a preferential prescription of an ACE inhibitor or BB.
描述2009年和2010年法国抗高血压药物的处方情况，并评估心血管疾病的存在对治疗特征的影响。
法国高血压防治联盟调查（FLAHS）针对居住在法国的35岁及以上具有代表性的个体样本进行。对于2009年和2010年的调查，研究了2292名宣称服用一种或多种抗高血压药物的受试者样本。除了调查当天服用的抗高血压药物的详细信息外，还收集了心血管疾病的个人病史。
在2292份至少有一张抗高血压处方中，处方频率如下：血管紧张素受体阻滞剂（ARB）（43%）、利尿剂（43%）、β受体阻滞剂（34%）、钙通道阻滞剂（CCB）（26%）、血管紧张素转换酶抑制剂（ACEI）（26%）、螺内酯（8%）、中枢和α受体阻滞剂（7%）、直接肾素抑制剂（DRI）（1%）。处方形式为单药治疗（42%）、两药联合治疗（37%）、三药联合治疗（16%）和四联或更多药物联合治疗（5%）。当采用三药联合治疗时，46%的情况是ACEI或ARB或DRI+利尿剂+β受体阻滞剂联合，30%的情况是ACEI或ARB或DRI+利尿剂+ACEI联合。24%的高血压患者报告有心血管疾病史或现患心血管疾病：冠状动脉疾病（13%）、心力衰竭（6%）、心律失常（5%）、中风（4%）、外周动脉疾病（4%）。β受体阻滞剂在患有冠状动脉疾病、心力衰竭和心律失常的高血压患者中使用更为普遍。ACE抑制剂在患有冠状动脉疾病、心力衰竭或中风的高血压患者中更为常见。钙通道阻滞剂在冠状动脉疾病或外周动脉疾病患者中更为频繁使用。血管紧张素受体阻滞剂在冠状动脉疾病患者中使用频率较低。
2009年至2010年法国最常处方的抗高血压药物是血管紧张素受体阻滞剂、利尿剂和β受体阻滞剂。24%的高血压患者宣称患有心血管疾病，这导致优先处方ACE抑制剂或β受体阻滞剂。
